Cerus Q3 product revenue $36.1M (+53% YoY); raises FY21 guidance to $127-129M

CERUS CORP

2022-Q3 EPS reported -$0.27

Total revenue $42.1M (+44% YoY); product revenue $36.1M (+53% YoY) driven by U.S. INTERCEPT platelet adoption.
Net loss $12.4M ($0.07/shr) improved from $14.1M ($0.08/shr) in Q3 2020.
Product gross margin 51.3% vs 53.6% YoY; gross profit record $18.5M.
FY21 product revenue guidance raised to $127-129M (from $118-122M), representing 38-40% growth.
Cash and short-term investments $120.0M at Sept 30; $55M notes due, $10M revolver drawn.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.